In a trial of ivosidenib for patients with newly-diagnosed IDH1-mutated AML, the CR/CRh rate was 42% and the median duration of response was not reached in 34 patients who received ivosidenib 500 mg once daily [136]. Here, IDH1 is linked to acute myeloid leukemia.